Evidence map›Paper›PMID 33488774›Full record

ArticleTherapeutic advances in neurological disorders2021

Real-world comparative safety and efficacy of tenecteplase

Klearchos Psychogios, Lina Palaiodimou, Aristeidis H Katsanos, Georgios Magoufis, Apostolos Safouris, Odysseas Kargiotis, Stavros Spiliopoulos, Ermioni Papageorgiou, Aikaterini Theodorou, Konstantinos Voumvourakis and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in neurological disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The efficacy and safety of intravenous thrombolysis with tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke.Current treatment options in cardiovascular medicine · 2023
    Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Klearchos PsychogiosAcute Stroke Unit, Metropolitan Hospital, Ethnarhou Makariou 9, Athens, Piraeus 18547, Greece.ORCID https://orcid.org/0000-0003-3993-2545
Lina PalaiodimouSecond Department of Neurology, Attikon University Hospital, School of Medicine, University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0001-7757-609X
Aristeidis H KatsanosDivision of Neurology, McMaster University/Population Health Research Institute, Hamilton, Canada.
Georgios MagoufisDepartment of Interventional Neuroradiology, Metropolitan Hospital, Piraeus, Greece.ORCID https://orcid.org/0000-0003-2440-3202
Apostolos SafourisAcute Stroke Unit, Metropolitan Hospital, Piraeus, Greece.
Odysseas KargiotisAcute Stroke Unit, Metropolitan Hospital, Piraeus, Greece.
Stavros SpiliopoulosSecond Department of Radiology, Division of Interventional Radiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
Ermioni PapageorgiouAcute Stroke Unit, Metropolitan Hospital, Piraeus, Greece.
Aikaterini TheodorouSecond Department of Neurology, Attikon University Hospital, School of Medicine, University of Athens, Athens, Greece.
Konstantinos VoumvourakisSecond Department of Neurology, Attikon University Hospital, School of Medicine, University of Athens, Athens, Greece.
Elias BroutzosSecond Department of Radiology, Division of Interventional Radiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
Elefterios StamboulisAcute Stroke Unit, Metropolitan Hospital, Piraeus, Greece.
Georgios TsivgoulisSecond Department of Neurology, Attikon University Hospital, School of Medicine, University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-0640-3797
National and Kapodistrian University of Athens · GRMetropolitan Hospital · GRPopulation Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsTenecteplase has recently emerged as an alternative thrombolytic agent in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO), possibly superior in achieving early reperfusion compared with alteplase. We aimed to compare the safety and efficacy of intravenous tenecteplase with intravenous alteplase for AIS patients with LVO in everyday clinical practice settings.

methodsWe prospectively evaluated patients with AIS due to LVO, treated with intravenous thrombolysis (IVT) with or without mechanical thrombectomy in two tertiary stroke centers. Patients were treated with standard-dose alteplase (0.9 mg/kg) or 0.25 mg/kg tenecteplase. Safety outcomes included prevalence of symptomatic intracranial hemorrhage (sICH) and mortality. Efficacy outcomes included averted thrombectomy, major neurological improvement at 24 h (defined as decrease in baseline NIHSS score of 8 points or greater) and functional status on discharge and on 3 months assessed by modified Rankin Scale (mRS).

resultsNineteen AIS patients with LVO received tenecteplase and 39 received alteplase. We observed a non-significant higher rate of averted thrombectomies (32%

conclusionThe present pilot observational study highlights that AIS patients with LVO treated with 0.25 mg/kg bolus administration of tenecteplase had increased likelihood to achieve early neurological improvement compared with AIS patients treated with alteplase, but this association was attenuated after adjustment for potential confounders. There were no significant differences in 3-month functional or safety outcomes between the two groups. This preliminary real-world observation requires independent confirmation in larger, multicenter studies.

Indexed as

alteplaseintravenous thrombolysislarge vessel occlusionmechanical thrombectomystroketenecteplase

Identifiers

PMID33488774
PMCPMC7809628
OpenAlexW3125508314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.